Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of LOncastuximab Tesirine in Patients With RElapsed/Refractory Diffuse LargeB-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) Who Have Progressive Disease After CAR T-cell Treatment

NCT06918912 is registered in ClinicalTrials.gov with Istituto Clinico Humanitas as lead sponsor.

NCT NCT06918912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06918912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of LOncastuximab Tesirine in Patients With RElapsed/Refractory Diffuse LargeB-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) Who Have Progressive Disease After CAR T-cell Treatment
Lead sponsor
Istituto Clinico Humanitas
Phase
Phase 2
Overall status
Recruiting
Start date
June 16, 2023
Completion date
June 30, 2027
Enrollment
50 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma treatment, diffuse large b-cell lymphoma, high-grade b-cell lymphoma (hgbcl), relapsed or refractory lymphoma